Mechanism of Action of DPP-4 Inhibitors—New Insights
Author:
Open Access
- 1 August 2012
- journal article
- other
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (8) , 2626-2628
Abstract
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that results in glucose-dependent insulin secretion, suppression of glucagon secretion, a delay in gastriKeywords
This publication has 19 references indexed in Scilit:
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1Diabetologia, 2005
- Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitorsDiabetologia, 2005
- Extrapancreatic Effects of GIP and GLP-1Hormone and Metabolic Research, 2004
- Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV InhibitorsDiabetes, 2004
- Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group studyThe Lancet, 2002
- The Glucagon-Like PeptidesEndocrine Reviews, 1999
- Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy SubjectsDiabetes, 1995
- Proglucagon processing in porcine and human pancreas.Journal of Biological Chemistry, 1994
- Pathogenesis of Age-Related Glucose Intolerance in Man: Insulin Resistance and Decreased β-Cell Function*The Journal of Clinical Endocrinology & Metabolism, 1985